Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxomemazine is a first-generation phenothiazine derivative antihistamine primarily used for the treatment of allergies, pruritic skin disorders, and cough. It acts as a sedating antihistamine by competitively binding to the histamine H1 receptor, thereby inhibiting the pharmacological effects of histamines. In addition to its antihistaminic action, oxomemazine exhibits anticholinergic and antiserotoninergic properties, contributing to its sedative effects. Its clinical uses include relief from hypersensitivity reactions and allergic skin conditions such as urticaria. Oxomemazine is known for causing sedation due to its ability to cross the blood-brain barrier[1][2][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxomemazine.